Ascendis Pharma Quarterly Income Statements Chart
Quarterly
|
Annual
Ascendis Pharma Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| consolidated statement of profit or loss | |||||||||
| revenue | 95,894 | 137,702 | 48,034 | 47,393 | 33,589 | 22,896 | 15,290 | 6,160 | |
| yoy | 185.49% | 501.42% | 214.15% | 669.37% | |||||
| qoq | -30.36% | 186.68% | 1.35% | 41.10% | 46.70% | 49.74% | 148.21% | ||
| cost of sales | 7,569 | 19,457 | 7,388 | 12,929 | 4,621 | 5,112 | 1,693 | 1,086 | |
| gross profit | 88,325 | 118,245 | 40,646 | 34,464 | 28,968 | 17,784 | 13,597 | ||
| yoy | 204.91% | 564.90% | 198.93% | ||||||
| qoq | -25.30% | 190.91% | 17.94% | 18.97% | 62.89% | 30.79% | |||
| gross margin % | 92.11% | 85.87% | 84.62% | 72.72% | 86.24% | 77.67% | 88.93% | 0% | |
| research and development costs | 70,687 | 90,881 | 111,439 | 105,021 | 106,114 | 108,618 | 97,431 | 90,383 | |
| selling, general and administrative expenses | 66,783 | 63,975 | 63,614 | 70,281 | 66,539 | 56,552 | 60,671 | 56,584 | |
| operating profit/ | -49,145 | ||||||||
| share of profit/(loss) of associates | -5,796 | ||||||||
| finance income | 3,575 | -33,128 | 4,142 | 35,761 | 45,135 | -21,616 | 20,326 | 71,127 | |
| finance expenses | 77,161 | 8,425 | 24,519 | 9,334 | 9,840 | 25,106 | 41,247 | 9,434 | |
| profit/(loss) before tax | -128,527 | ||||||||
| income taxes/ | -2,508 | ||||||||
| net profit/(loss) for the period | -131,035 | ||||||||
| attributable to owners of the company | -131,035 | -86,878 | -162,223 | -121,433 | -110,914 | -207,418 | -168,955 | -81,319 | |
| basic and diluted earnings/(loss) per share | |||||||||
| number of shares used for calculation | 56,883,257 | 14,048,739 | 56,272,698 | 56,218,257 | 56,091,927 | 14,028,945.5 | 55,831,561 | 55,805,486 | |
| consolidated statement of comprehensive income or | |||||||||
| other comprehensive income/ | |||||||||
| items that may be reclassified subsequently to profit or loss: | |||||||||
| exchange differences on translating foreign operations | 63 | -1,499 | 571 | -1,016 | -787 | 2,211 | -2,207 | -757 | |
| other comprehensive income/(loss) for the period, net of tax | 63 | ||||||||
| total comprehensive income/(loss) for the period, net of tax | -130,972 | ||||||||
| operating profit / | -104,732.5 | -134,407 | -140,838 | -143,685 | -103,607 | -144,505 | -141,893 | ||
| share of profit / (loss) of associate | -3,867.75 | -6,794 | -7,451 | -1,227 | -2,434 | -3,696 | -1,166 | ||
| profit / (loss) before tax | -98,264 | -161,578 | -121,862 | -109,617 | -93,937 | -169,122 | -81,366 | ||
| income taxes | -378.25 | -645 | 429 | -1,297 | |||||
| net profit / (loss) for the period | -98,642.25 | -162,223 | -121,433 | -110,914 | -93,944 | -168,955 | -81,319 | ||
| basic and diluted earnings / (loss) per share | |||||||||
| statement of comprehensive income | |||||||||
| other comprehensive income / | |||||||||
| other comprehensive income / (loss) for the period, net of tax | -308 | 571 | -1,016 | -787 | -634.5 | -2,207 | -757 | ||
| total comprehensive income / (loss) for the period, net of tax | -98,950.25 | -161,652 | -122,449 | -111,701 | -94,578.5 | -171,162 | -82,076 | ||
| statement of profit or loss | |||||||||
| tax on profit / (loss) for the period | -7 | 167 | 47 | ||||||
| gross profit / | 5,074 |
We provide you with 20 years income statements for Ascendis Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ascendis Pharma stock. Explore the full financial landscape of Ascendis Pharma stock with our expertly curated income statements.
The information provided in this report about Ascendis Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.